載入中
NASDAQHealthcareBiotechnology
最新資料
US$25.76
+US$0.04 · +0.16%
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
前收盤價
US$25.76
+US$0.04 · +0.16%
盤中時間採用ET。市場資料可能有所延遲。
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
日內區間
目前US$25.76
52週區間
目前US$25.76
盤中時間採用ET。市場資料可能有所延遲。
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
日內區間
目前US$25.76
52週區間
目前US$25.76
| 項目（USD） | 2025會計年度 |
|---|---|
| 研究與開發 | 7661.4萬 USD |
| 銷售、一般及管理費用 | 1467.8萬 USD |
| 營業費用 | 9129.2萬 USD |
| 利息收入 | 617.7萬 USD |
| 折舊和攤銷 | 4.2萬 USD |
| 營業利益 | −9129.2萬 USD |
| 淨利 | −8520.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$60.00
上漲空間 132.92%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1856.11萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1220.1萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF676.85萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH362.47萬0.79%4.62億 USD0.35%US$64.65+1.60%
Vanguard Russell 2000 ETFVTWO341.49萬0.02%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO295.86萬0.02%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA239.13萬0.01%218.24億 USD0.03%US$32.79+0.40%
T. Rowe Price Small-Mid Cap ETFTMSL189.61萬0.06%30.87億 USD0.55%US$41.18+0.59%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAT. Rowe Price Small-Mid Cap ETFTMSLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
